Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Week in Review: iCarbonX "Ecosystem" Invests $400 Million in Seven Companies

publication date: Jan 7, 2017
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

iCarbonX, the Shenzhen big data/artificial intelligence health company, formed The Digital Life Alliance with seven outside life science companies, complete with a total investment of nearly $400 million from the iCarbonX ecosystem; Ascletis of Hangzhou completed a $100 million series B financing to build a sales force and acquire additional liver disease drugs; Nanjing Frontier Biotech, which is developing a novel AIDS treatment, raised $43 million in a Series C round; MabSpace of Suzhou will collaborate with San Diego's Ambrx to discover multiple novel antibody drug conjugates; Lee's Pharm in-licensed China rights to a clinic-ready treatment for wet age-related macular degeneration from TOT Biopharma of Suzhou; BIT Group of Germany officially opened EMD Shenzhen, a Joint Venture with EDAN Instruments that offers CMO services for IVD products; Taiwan's TLC reported positive top-line results from the Phase I/II trial of TLC599, a sustained release corticosteroid; and Beijing's Yisheng Biopharma was granted US Orphan Drug designation for a novel PIKA rabies vaccine. More details....

Stock Symbols: (HK: 950) (TT: 4152)

Share this with colleagues:  

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...